BioCentury | Jun 13, 2020
Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

mAbs against new myeloid checkpoint OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells....
BioCentury | May 28, 2020
Distillery Therapeutics

Epigenetic enzyme Tet1 as osteoarthritis target

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Inhibiting Tet1, an epigenetic enzyme that methylates cytosine, could treat osteoarthritis. In patient-derived chondrocytes, an shRNA against Tet1 reduced mRNA levels of two disease markers, MMP3 and MMP13, as...
BioCentury | Apr 11, 2020
Product Development

COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker

Eli Lilly’s rheumatoid arthritis drug Olumiant baricitinib has become the second treatment added to NIH’s COVID-19 master protocol, joining Gilead’s remdesivir. Separately, U.S. representatives called on FDA to ensure diagnostics are accurate, and ASCO launched...
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

Protease inhibitor blocks COVID-19 viral fusion Camostat mesylate, a TMPRSS2 inhibitor already approved in Japan for digestive system indications, has become one of the latest drugs that could be repurposed to treat COVID-19. A team...
BioCentury | Jan 9, 2020
Targets & Mechanisms

Cancer's trajectory, as viewed by targets at AACR, ASCO and ASH

...to make appearances at the conferences. Emerging targets also featured extracellular matrix proteins, such as MMP7...
...factor (TNF) receptor superfamily member 17 CEBPA - CCAAT enhancer binding protein alpha MMP7 - Matrix metalloproteinase 7...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jul 10, 2019
Distillery Therapeutics

Reducing adipogenesis by fibroadipogenic precursors could treat limb-girdle muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Inhibiting ANXA2 or MMP could treat limb-girdle muscular dystrophy (LGMD2B) by preventing fibroadipogenic precursor cells from accumulating and undergoing adipogenesis. In three patients with LGMD2B, which is caused by...
BioCentury | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
Items per page:
1 - 10 of 513